Company / Return on Assets (ROA)
Avalo Therapeutics, Inc. Return on Assets (ROA) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-67.2%
FY2025
5-year range
-150.3% / -23.3%
FY2021-FY2025
Trend
-188.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Assets (ROA) has fluctuated over the past 9 years, ranging from -150.3% in FY2023 to 27.7% in FY2017.
Based on SEC 10-K filings.
-67.2% in FY2025 with a 5-year CAGR of +77.9%.
Improved from -150.3% to -67.2% over the past 2 years.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +57.6pp
- 5-Year Change
- +77.9pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on assets (roa) decreased 188.3% year-over-year.
- Peak return on assets (roa) was recorded in FY2017.
- Lowest return on assets (roa) in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -67.2% | -188.3% |
| FY2024 | -23.3% | +84.5% |
| FY2023 | -150.3% | -20.4% |
| FY2022 | -124.8% | -18.7% |
| FY2021 | -105.2% | +27.5% |
| FY2020 | -145.1% | -226.1% |
| FY2019 | -44.5% | +21.9% |
| FY2018 | -57.0% | -305.6% |
| FY2017 | 27.7% | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026